Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Respiratory Clinical Trials Strategy

Sanofi Showcases Long-Term Benefits Of Dupixent For Severe Asthma

Another Boost For Blockbuster

Executive Summary

While many analysts have been focusing on the growth potential of Regeneron-partnered Dupixent in atopic dermatitis, the French giant has been highlighting the biologic's benefits for asthma with three-year data presented at the ERS meeting.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward

Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.

New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar

Several high-profile products including Dupixent gain approvals in China.

Table

View full table

Topics

Related Companies

Tags:
Respiratory Clinical Trials Strategy
Latest Headlines

Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

See All
UsernamePublicRestriction

Register

SC142929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By